Adaptive Biotechnologies Corp at JPMorgan Healthcare Conference Transcript
All right. Good afternoon. I hope everybody is enjoying the conference so far. Welcome to day 1 afternoon of the JPMorgan Healthcare Conference. I'm Julia Cheng. I cover life science tools and diagnostics at JPMorgan. And it's my great pleasure to introduce you to our next company presentation today by Adaptive. So with that, I'll turn it over to Chad.
Thank you, Julia. I'm Chad Robins, I'm the CEO of Adaptive Biotechnologies. I want to wish everyone a happy new year for those in the room and those listening in by webcast. Momentum in Adaptive Biotechnologies is building. We're driving revenue growth. We're advancing our pipeline, and we're managing our operating expenses with a very strong cash position.
I want to remind you today, I will be making forward-looking statements both in the presentation and in the question-and-answer session afterwards. The mission of Adaptive is and always has been to translate the genetics of T cell and B cell receptors
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |